Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) Latest Company News

Sep 20, 2026, 07:34 UTC
Shandong Zibo Xinda Pharmaceutical, a wholly owned subsidiary of Shandong Xinhua Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for 5mg donepezil hydrochloride orally disintegrating tablets.
Source:
- finance.sina.cn
Sep 18, 2026, 09:16 UTC
Shandong Xinhua Pharmaceutical received drug registration certificates from China's National Medical Products Administration for its oral concentrated solution of magnesium sulfate, sodium sulfate and potassium sulfate and oral levocarnitine solution.
Source:
- aastocks.com
- finance.sina.cn
Aug 31, 2026, 08:48 UTC
Xinhua Pharmaceutical's wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical received approval for its azithromycin tablets 0.25g to pass generic drug consistency evaluation, enabling market entry.
Source:
- finance.sina.cn
Aug 28, 2026, 08:18 UTC
Xinhua Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for its dapoxetine hydrochloride tablets, a 30mg Class 4 chemical prescription drug for treating premature ejaculation in men aged 18-64, approved in August 2026.
Source:
- finance.sina.cn
Aug 25, 2026, 09:06 UTC
Xinhua Pharmaceutical announced its interim results for the six months ended June 2026, with revenue of RMB 4.358 billion, down 6.06% year-on-year, and net profit of RMB 149 million, down 33.35% year-on-year.
Source:
- aastocks.com
Aug 21, 2026, 08:53 UTC
Xinhua Pharmaceutical announced that it received the Drug Registration Certificate for Dapagliflozin Tablets from the National Medical Products Administration in August 2026, following its application submitted to CDE in March 2025.
Source:
- finance.sina.cn
- aastocks.com
Jul 4, 2026, 00:38 UTC
Xinhua Pharmaceutical initiated the Phase I clinical trial of its first-in-class innovative drug LXH-1211 tablets for pulmonary arterial hypertension.
Source:
- finance.sina.cn

00719.HK

Shandong Zibo Xinda Pharmaceutical, a wholly owned subsidiary of Shandong Xinhua Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for 5mg donepezil hydrochloride orally disintegrating tablets.

Shandong Xinhua Pharmaceutical received drug registration certificates from China's National Medical Products Administration for its oral concentrated solution of magnesium sulfate, sodium sulfate and potassium sulfate and oral levocarnitine solution.

Xinhua Pharmaceutical's wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical received approval for its azithromycin tablets 0.25g to pass generic drug consistency evaluation, enabling market entry.

Xinhua Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for its dapoxetine hydrochloride tablets, a 30mg Class 4 chemical prescription drug for treating premature ejaculation in men aged 18-64, approved in August 2026.

Xinhua Pharmaceutical announced its interim results for the six months ended June 2026, with revenue of RMB 4.358 billion, down 6.06% year-on-year, and net profit of RMB 149 million, down 33.35% year-on-year.

Xinhua Pharmaceutical announced that it received the Drug Registration Certificate for Dapagliflozin Tablets from the National Medical Products Administration in August 2026, following its application submitted to CDE in March 2025.

Xinhua Pharmaceutical initiated the Phase I clinical trial of its first-in-class innovative drug LXH-1211 tablets for pulmonary arterial hypertension.